Can the Gupta siblings solve Lupin's US puzzle? : vimarsana.

The US has been a sore point in the pharma company’s business. A turnaround is in the works.Lupin’s US revenue has shrunk while its margins are the worst among pharma companies. A series of setbacks—regulatory troubles, price erosion and impairments—have impacted the company.

Related Keywords

Tarapur , Maharashtra , India , Australia , Japan , France , Brazil , Palghar , Madhya Pradesh , Southern Cross , Victoria , French , Japanese , Australian , Desh Bandu , Manju Gupta , Ramesh Swaminathan , Desh Bandhu , Novel Laboratories Inc , Bausch Medical Companies Inc , Southern Cross Pharmaceuticals , Drug Administration , Gavis Pharmaceuticals , Symbiomix Therapeutics , World Health Organization , Boehringer Ingelheim , Novel Laboratories , Nilesh , Vinitha , Lupin , Us , Desh Bandu Gupta , Lupin Ltd , Us Market , Pharmaceuticals , Fda ,